Clinical status of agents being developed for leishmaniasis

@article{Berman2005ClinicalSO,
  title={Clinical status of agents being developed for leishmaniasis},
  author={J. Berman},
  journal={Expert Opinion on Investigational Drugs},
  year={2005},
  volume={14},
  pages={1337 - 1346}
}
  • J. Berman
  • Published 2005
  • Medicine
  • Expert Opinion on Investigational Drugs
Leishmaniasis, which exists in both visceral and cutaneous forms, is currently treated with intramuscular antimony or intravenous amphotericin B. The primary unmet need is for oral therapy. Of the several drugs in clinical development, miltefosine is unique in being an oral agent with efficacy against both forms of the disease. Sitamaquine is an oral agent with substantial but not sufficient efficacy against visceral disease. Oral fluconazole has been shown to be more effective than placebo in… Expand
54 Citations
Avaliation the Therapeutic Efficacy of Fluconazol
  • 1
Modes of action of Leishmanicidal antimicrobial peptides.
  • 34
Treatment options for visceral leishmaniasis
  • 43
[Cutaneous leishmaniasis in rheumatoid arthritis].
  • 1
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 67 REFERENCES
Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.
  • 435
Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator.
  • 194
  • PDF
Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis.
  • 146
Oral miltefosine for Indian visceral leishmaniasis.
  • 660
  • PDF
Trial of oral miltefosine for visceral leishmaniasis
  • 220
Itraconazole and leishmaniasis: a randomised double-blind trial in cutaneous disease.
  • 70
Allopurinol in the treatment of American cutaneous leishmaniasis.
  • 134
Cutaneous leishmaniasis in a Kosovan child treated with oral fluconazole
  • 17
...
1
2
3
4
5
...